R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 52.75
-0.95 (-1.77%)
Sep 1, 2026, 4:00 PM EDT
R&G PharmaStudies Market Cap
R&G PharmaStudies has a market cap or net worth of 5.06 billion as of September 1, 2026. Its market cap has increased by 0.44% in one year.
Market Cap
5.06B
Enterprise Value
3.44B
Revenue
939.31M
Ranking
n/a
PE Ratio
42.25
Stock Price
52.75
ChartMarket Cap Chart
Since August 2, 2022, R&G PharmaStudies's market cap has decreased from 5.40B to 5.06B, a decrease of -6.24%. That is a compound annual growth rate of -1.57%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 1, 2026 | 5.06B | -10.63% |
| Dec 31, 2025 | 5.67B | 19.12% |
| Dec 31, 2024 | 4.76B | -23.17% |
| Dec 29, 2023 | 6.19B | 25.30% |
| Dec 30, 2022 | 4.94B | -8.52% |
| Aug 2, 2022 | 5.40B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| PharmaResources (Shanghai) | 5.53B |
| Hangzhou Biotest Biotech | 5.41B |
| Shouyao Holdings (Beijing) Co., LTD. | 5.20B |
| Shenzhen Weiguang Biological Products | 5.15B |
| Novoprotein Scientific | 5.11B |
| Boji Medical Technology | 5.07B |
| Beijing Konruns Pharmaceutical | 4.84B |
| ChemPartner PharmaTech | 4.82B |